SummitTX Capital L.P. Has $2.38 Million Stock Position in Celcuity, Inc. $CELC

SummitTX Capital L.P. lifted its position in Celcuity, Inc. (NASDAQ:CELC) by 54.7% in the first quarter, Holdings Channel.com reports. The institutional investor owned 20,812 shares of the company’s stock after buying an additional 7,363 shares during the period. SummitTX Capital L.P.’s holdings in Celcuity were worth $2,375,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in CELC. NEA Management Company LLC lifted its holdings in Celcuity by 64.9% during the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after acquiring an additional 1,391,300 shares in the last quarter. Avoro Capital Advisors LLC bought a new stake in shares of Celcuity in the fourth quarter worth about $310,302,000. Soleus Capital Management L.P. increased its holdings in shares of Celcuity by 17.0% in the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after acquiring an additional 437,696 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Celcuity by 10.7% during the fourth quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock worth $227,351,000 after purchasing an additional 220,386 shares during the period. Finally, State Street Corp raised its position in shares of Celcuity by 126.6% during the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after purchasing an additional 914,887 shares during the period. Institutional investors and hedge funds own 63.33% of the company’s stock.

Insiders Place Their Bets

In other news, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director owned 65,000 shares of the company’s stock, valued at $9,144,200. The trade was a 27.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the transaction, the director owned 6,760 shares of the company’s stock, valued at $949,509.60. The trade was a 57.11% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.33% of the company’s stock.

Celcuity Trading Up 0.2%

NASDAQ CELC opened at $82.46 on Wednesday. The stock has a market capitalization of $4.02 billion, a price-to-earnings ratio of -21.14 and a beta of 0.16. The stock’s 50 day moving average price is $102.07 and its two-hundred day moving average price is $110.07. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. Celcuity, Inc. has a 52 week low of $34.30 and a 52 week high of $151.02.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. As a group, analysts anticipate that Celcuity, Inc. will post -3.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $157.00 price target on shares of Celcuity in a report on Friday, May 15th. Weiss Ratings upgraded shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Macquarie Infrastructure set a $160.00 price objective on shares of Celcuity in a research report on Thursday, May 28th. Leerink Partners set a $155.00 target price on shares of Celcuity in a research note on Tuesday, June 2nd. Finally, Stifel Nicolaus set a $150.00 target price on Celcuity in a report on Monday, May 4th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $155.18.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.